MESO

Mesoblast Stock Analysis

AI Rating

Low
  • Quality2/10
  • Growth↓ 4/10
  • Value↓ 0/10
Mesoblast sales and earnings growth
MESO Growth
Neutral
  • Revenue Y/Y↑ 775.64%
  • EPS Y/Y↑ 14.40%
  • FCF Y/Y↓ -2.52%
Mesoblast gross and profit margin trends
MESO Profitability
Neutral
  • Gross margin ↑ 80.50%
  • EPS margin↓ -144.30%
  • ROIC 5Y↓ -93.58%
Mesoblast net debt vs free cash flow
MESO Risk
Great
  • Debt / Equity↓ 0.2
  • Debt / FCF↓ 0.1
  • Interest coverage↓ -2.4

Mesoblast stock volatility is higher than the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗